DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT04186494

CompletedPhase NA

Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea

The Benefit of a Liraglutide-based Weight Management Alone or in Addition to Standard CPAP Therapy on Metabolic Function in Patients With Obstructive Sleep Apnoea (OSA) - an Explorative, Proof-of-concept Study

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

30

actual

Study population

Obesity / overweight, Sleep apnea

Key I/E criterion

•BMI 30-40

Primary endpoint

•HOMA-IR (insulin sensitivity)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04186494
Org study IDRS19-023

Timeline

Milestones

Study start2019-12-02actual
Study first posted2019-12-04actual
Primary completion2021-12-31actual
Study completion2022-07-31actual
Last update posted2023-12-18actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweightSleep apnea

Eligibility

Who can enroll

Minimum age18 Years
Maximum age60 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Newly diagnosed moderate-severe OSA (by standard PSG)
•Body mass index between 30 - 40
•Age 18 - 60 years
•Able to provide written, informed consent

Exclusion criteria

•Pregnancy
•Requirement for supplemental oxygen
•Previous diagnosis of OSA or previous CPAP treatment
•Diagnosis of Diabetes
•Previous treatment with GLP-1 analogue
•Previous surgical treatment for obesity
•Active treatment for malignancy or severe psychiatric disorder
•Acute coronary syndrome or stroke within 3 months prior to study
•History of decompensated heart failure
•Professional drivers or drivers with a history of road-traffic accident due to sleepiness
•Severe excessive daytime sleepiness defined as Epworth sleepiness scale >15

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers
3
Glycemic / diabetes
2
Cardiovascular outcomes
1
Weight & body composition
1
Other clinical outcomes
1

Cardiovascular outcomes

1 endpoint
Secondary/protocol endpoint

Coronary artery calcification

Time frame:6 months

change from baseline, improvement

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Weight

Time frame:6 months

BMI, change

change from baseline, improvement

Glycemic / diabetes

2 endpoints
Primary/protocol endpoint

Insulin resistance

Time frame:6 months

HOMA-IR (insulin sensitivity)

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Glucose tolerance

Time frame:6 months

change from baseline, improvement

Cardiometabolic biomarkers

3 endpoints
Secondary/protocol endpoint

Blood pressure

Time frame:6 months

change from baseline, improvement

Secondary/protocol endpoint

Endothelial function

Time frame:6 months

change from baseline, improvement

Secondary/protocol endpoint

Vascular inflammation

Time frame:6 months

change from baseline, improvement

Other clinical outcomes

1 endpoint
Secondary/protocol endpoint

OSA Severity

Time frame:6 months

AHI, change

change from baseline, improvement

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.